Takeda Pharmaceuticals Europe Ltd.

GPTKB entity

Statements (56)
Predicate Object
gptkbp:instanceOf gptkb:Company
gptkbp:acquisition gptkb:Shire_plc
Acquired Envoy Therapeutics in 2016
Acquired Shire in 2019
Acquired_Ariad_Pharmaceuticals_in_2017
Acquired_Nycomed_in_2011
Acquired_TiGenix_in_2018
gptkbp:awards received accolades for workplace culture
recognized for innovation in pharmaceuticals
awarded for corporate social responsibility
won awards for diversity and inclusion initiatives
gptkbp:CEO gptkb:Christophe_Weber
gptkbp:clinicalTrials conducts numerous clinical trials
gptkbp:communityInvolvement engages in local community projects
supports various health initiatives
gptkbp:employees over 30,000
gptkbp:focusesOn biopharmaceuticals
gptkbp:founded 1781
gptkbp:globalPresence operates in over 70 countries
gptkbp:headCoach approximately 50,000 globally
gptkbp:headquarters gptkb:Zurich,_Switzerland
https://www.w3.org/2000/01/rdf-schema#label Takeda Pharmaceuticals Europe Ltd.
gptkbp:investmentFocus invests heavily in R&D
invests in sustainable practices
invests in digital health technologies
invests in patient-centric solutions
gptkbp:mission to strive towards better health for people worldwide
gptkbp:operatesIn Europe
gptkbp:parentCompany gptkb:Takeda_Pharmaceutical_Company_Limited
gptkbp:partnerships biotech companies
various academic institutions
gptkbp:products vaccines
oncology drugs
gastroenterology drugs
rare diseases drugs
gptkbp:research_areas oncology
rare diseases
neuroscience
gastroenterology
gptkbp:researchAndDevelopment focus on neuroscience
focus on immunology
focus on hematology
gptkbp:revenue $17.3 billion (2022)
gptkbp:stockSymbol 4502 (TSE)
TAK_(NYSE)
gptkbp:subsidiary gptkb:Takeda_Pharmaceutical_Company_Limited
gptkbp:sustainabilityInitiatives community engagement
environmental responsibility
patient access programs
gptkbp:values honesty
teamwork
fairness
integrity
perseverance
gptkbp:vision to be a global leader in the biopharmaceutical industry
gptkbp:website www.takeda.com